These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30733972)

  • 1. A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan.
    Qiu W; Zhang C; Wang S; Yu X; Wang Q; Zeng D; Du P; Ma J; Zheng Y; Pang B; Yu Y; Long F; Pang X; Sun Z
    J Immunol Res; 2019; 2019():3017360. PubMed ID: 30733972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.
    Wild R; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Luo FR; Camuso A; McGlinchey K; Rose WC
    Mol Cancer Ther; 2006 Jan; 5(1):104-13. PubMed ID: 16432168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
    Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
    Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a new dual-targeting fully human antibody with potent antitumor activity against nasopharyngeal carcinoma.
    Xie S; Zhu X; Li Y; Li L; Si Y; Yang N
    Biol Chem; 2015 Aug; 396(8):917-21. PubMed ID: 25429597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
    Wen F; Li Q
    World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer.
    Park JE; Jin MH; Hur M; Nam AR; Bang JH; Won J; Oh DY; Bang YJ
    Gastric Cancer; 2019 Sep; 22(5):932-940. PubMed ID: 30815759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.
    Rios-Doria J; Sabol D; Chesebrough J; Stewart D; Xu L; Tammali R; Cheng L; Du Q; Schifferli K; Rothstein R; Leow CC; Heidbrink-Thompson J; Jin X; Gao C; Friedman J; Wilkinson B; Damschroder M; Pierce AJ; Hollingsworth RE; Tice DA; Michelotti EF
    Mol Cancer Ther; 2015 Jul; 14(7):1637-49. PubMed ID: 25948294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
    Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
    Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
    Gong JH; Liu XJ; Li Y; Zhen YS
    Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
    Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
    Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
    Prewett M; Bassi R; Paz K; Amatulli M; Deevi D; Li H; Wang S; Witte L; Samakoglu S; Tonra JR
    Anticancer Res; 2011 Jun; 31(6):2149-60. PubMed ID: 21737635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.
    Yi CH; Ruan CP; Wang H; Xu XY; Zhao YP; Fang M; Ji J; Gu X; Gao CF
    Acta Pharmacol Sin; 2014 Nov; 35(11):1439-46. PubMed ID: 25263334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12.
    Dong Q; Shi B; Zhou M; Gao H; Luo X; Li Z; Jiang H
    Front Med; 2019 Feb; 13(1):83-93. PubMed ID: 30671888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
    Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
    Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
    Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
    Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
    Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.